日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Early prediction of vasopressor initiation in ICU sepsis patients using an interpretable EHR-based ML model

利用基于可解释的电子病历机器学习模型,对ICU脓毒症患者早期预测血管加压药的使用

Duval, Lucas; Villié, Antoine; Zheng, Fei; Terraz, Gabriel; Blein, Sophie; Duperchy, Esther; Everett, Martin; Frieling, Johan; Llitjos, Jean-François; Bodinier, Maxime

A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response

一项随机、双盲、3期临床试验,比较利地尼唑与万古霉素治疗艰难梭菌感染的安全性和有效性:临床结果及微生物组和代谢组与疗效的相关性研究

Okhuysen, Pablo C; Ramesh, Mayur S; Louie, Thomas; Kiknadze, Nino; Torre-Cisneros, Julian; de Oliveira, Claudia Murta; Van Steenkiste, Christophe; Stychneuskaya, Alena; Garey, Kevin W; Garcia-Diaz, Julia; Li, Jianling; Duperchy, Esther; Chang, Betty Y; Sukbuntherng, Juthamas; Montoya, Jose G; Styles, Lori; Clow, Fong; James, Danelle; Dubberke, Erik R; Wilcox, Mark

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic

精准艰难梭菌抗生素 Ridinilazole 的新型 DNA 结合机制

Clive S Mason, Tim Avis, Chenlin Hu, Nabeetha Nagalingam, Manikhandan Mudaliar, Chris Coward, Khurshida Begum, Kathleen Gajewski, M Jahangir Alam, Eugenie Bassères, Stephen Moss, Stefanie Reich, Esther Duperchy, Keith R Fox, Kevin W Garey, David J Powell

1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile

1052. 对利地尼唑(一种目前正在进行 III 期临床试验的选择性抗生素,用于治疗艰难梭菌感染)的 DNA 结合特性进行表征

Gao, Ling; Qiu, Fan; Cao, Hao; Li, Hao; Dai, Gonghua; Ma, Teng; Gong, Yanshan; Luo, Wei; Zhu, Dongling; Qiu, Zhixuan; Zhu, Ping; Chu, Shuguang; Yang, Huangtian; Liu, Zhongmin; Mason, Clive; Avis, Tim; Coward, Chris; Powell, David; Duperchy, Esther; Hu, Chenlin; Jahangir Alam, M; Begum, Khurshida; Garey, Kevin W; Reich, Stefanie; Moss, Stephen

Direct modifications of the cyclic peptide Polymyxin B leading to analogues with enhanced in vitro antibacterial activity

对环状肽多粘菌素B进行直接修饰,可得到体外抗菌活性增强的类似物。

Brown, Pamela; Abdulle, Omar; Boakes, Steven; Duperchy, Esther; Moss, Stephen; Simonovic, Mona; Stanway, Steven; Wilson, Antoinette; Dawson, Michael J

1361. Pharmacokinetics and Safety of Ridinilazole (RDZ), a Potential New Therapy for Clostridium difficile Infection (CDI): From Animal Models to Patients

1361. 利地尼唑 (RDZ) 的药代动力学和安全性:一种治疗艰难梭菌感染 (CDI) 的潜在新疗法:从动物模型到患者

Danish, Lubna; Siddiq, Riffat; Jahan, Sarwat; Taneez, Mehwish; Khan, Manzoor; Sandhu, Marva; Natividad Bisquera, Nichole Andrea; Mirasol, Roberto Cachola; Pruskowski, Kaitlin A; Britton, Garrett W; Mitchell, Thomas A; Cancio, Leopoldo C; Cari, Evelyn Villacorta; Leedy, Nicole; Ribes, Julie A; Soria, Jaime; Myint, Thein; Alaoui, A; Oumedjbeur, K; Djinbachian, R; Marchand, E; Marques, P; Hammar, C; Pohl, H; Bouin, M; Deslandres, E; Bouchard, S; von Renteln, D; Duperchy, Esther; Chowdhury, Sumita; Vickers, Richard; Robinson, Neil

Genomic comparisons among Escherichia coli strains B, K-12, and O157:H7 using IS elements as molecular markers

利用IS元件作为分子标记对大肠杆菌B、K-12和O157:H7菌株进行基因组比较

Schneider, Dominique; Duperchy, Esther; Depeyrot, Joelle; Coursange, Evelyne; Lenski, Richard; Blot, Michel

Long-term experimental evolution in Escherichia coli. IX. Characterization of insertion sequence-mediated mutations and rearrangements

大肠杆菌的长期实验进化。IX. 插入序列介导的突变和重排的特征分析

Schneider, D; Duperchy, E; Coursange, E; Lenski, R E; Blot, M